KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL

KSD-101

Patients will receive approximately 5x10\^6 DC vaccine via subcutaneous injections bi-weekly,total 3-5 times.

Trial Locations (1)

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors

collaborator

Kousai Bio Co., Ltd.

OTHER

lead

Sun Yat-sen University

OTHER

NCT06370026 - KSD-101 Therapy for Standard Treatment Failed EBV-associated NPC: an Exploratory Clinical Trial | Biotech Hunter | Biotech Hunter